Abstract
1. The pharmacokinetics of recombinant erythropoietin, r-Epo, were evaluated after intravenous and subcutaneous administration of 50 u kg-1 to six healthy male volunteers. 2. The calculated mean values (+/- s.d.) for volume of distribution at steady state and clearance after an i.v. dose were 76 (+/- 33) ml kg-1 and 12 (+/- 3) ml h-1 kg-1, respectively. 3. Serum concentrations of r-Epo peaked at 13 (+/- 6) h after the s.c. dose and the bioavailability over 72 h was 36 (+/- 23)%. The mean residence time and half-life of erythropoietin were 6.2 (+/- 1.0) and 4.5 (+/- 0.9) h respectively after i.v. and 46 (+/- 18) and 25 (+/- 12) h after s.c. administration. 4. The results demonstrate the possibility of changing the profile of the concentration-time curve by changing the mode of administration of r-Epo, with implications for the time-course of clinical response.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Egrie J. C., Cotes P. M., Lane J., Gaines Das R. E., Tam R. C. Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen. J Immunol Methods. 1987 May 20;99(2):235–241. doi: 10.1016/0022-1759(87)90133-5. [DOI] [PubMed] [Google Scholar]
- Erslev A. J., Wilson J., Caro J. Erythropoietin titers in anemic, nonuremic patients. J Lab Clin Med. 1987 Apr;109(4):429–433. [PubMed] [Google Scholar]
- Eschbach J. W., Egrie J. C., Downing M. R., Browne J. K., Adamson J. W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987 Jan 8;316(2):73–78. doi: 10.1056/NEJM198701083160203. [DOI] [PubMed] [Google Scholar]
- Gomeni R. PHARM--an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med. 1984;14(1):25–34. doi: 10.1016/0010-4825(84)90017-9. [DOI] [PubMed] [Google Scholar]
- Naets J. P., Garcia J. F., Tousaaint C., Buset M., Waks D. Radioimmunoassay of erythropoietin in chronic uraemia or anephric patients. Scand J Haematol. 1986 Nov;37(5):390–394. doi: 10.1111/j.1600-0609.1986.tb02626.x. [DOI] [PubMed] [Google Scholar]
- Rege A. B., Brookins J., Fisher J. W. A radioimmunoassay for erythropoietin: serum levels in normal human subjects and patients with hemopoietic disorders. J Lab Clin Med. 1982 Dec;100(6):829–843. [PubMed] [Google Scholar]
- Sinai-Trieman L., Salusky I. B., Fine R. N. Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis. J Pediatr. 1989 Apr;114(4 Pt 1):550–554. doi: 10.1016/s0022-3476(89)80692-4. [DOI] [PubMed] [Google Scholar]
- Stevens J. M., Strong C. A., Oliver D. O., Winearls C. G., Cotes P. M. Subcutaneous erythropoietin and peritoneal dialysis. Lancet. 1989 Jun 17;1(8651):1388–1389. doi: 10.1016/s0140-6736(89)92832-8. [DOI] [PubMed] [Google Scholar]
- Sundal E., Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant. 1989;4(11):979–987. doi: 10.1093/ndt/4.11.979. [DOI] [PubMed] [Google Scholar]
- Winearls C. G., Oliver D. O., Pippard M. J., Reid C., Downing M. R., Cotes P. M. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986 Nov 22;2(8517):1175–1178. doi: 10.1016/s0140-6736(86)92192-6. [DOI] [PubMed] [Google Scholar]